CN114072408A - 作为porcupine抑制剂的化合物及其应用 - Google Patents

作为porcupine抑制剂的化合物及其应用 Download PDF

Info

Publication number
CN114072408A
CN114072408A CN202080049913.6A CN202080049913A CN114072408A CN 114072408 A CN114072408 A CN 114072408A CN 202080049913 A CN202080049913 A CN 202080049913A CN 114072408 A CN114072408 A CN 114072408A
Authority
CN
China
Prior art keywords
compound
mmol
isomer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080049913.6A
Other languages
English (en)
Other versions
CN114072408B (zh
Inventor
徐雄彬
陈毅
王才林
冯如
江文
吴凌云
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN114072408A publication Critical patent/CN114072408A/zh
Application granted granted Critical
Publication of CN114072408B publication Critical patent/CN114072408B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一类porcupine抑制剂，具体公开了式(I)所示化合物、其药学上可接受的盐或其异构体。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN202080049913.6A 2019-07-08 2020-07-08 作为porcupine抑制剂的化合物及其应用 Active CN114072408B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910613678X 2019-07-08
CN201910613678 2019-07-08
PCT/CN2020/100771 WO2021004467A1 (zh) 2019-07-08 2020-07-08 作为porcupine抑制剂的化合物及其应用

Publications (2)

Publication Number Publication Date
CN114072408A true CN114072408A (zh) 2022-02-18
CN114072408B CN114072408B (zh) 2023-05-12

Family

ID=74114366

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049913.6A Active CN114072408B (zh) 2019-07-08 2020-07-08 作为porcupine抑制剂的化合物及其应用

Country Status (3)

Country Link
US (1) US20220281873A1 (zh)
CN (1) CN114072408B (zh)
WO (1) WO2021004467A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072263A1 (zh) * 2021-10-29 2023-05-04 南京明德新药研发有限公司 5-取代的吡啶-2(1h)-酮类化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010088518A2 (en) * 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN105142641A (zh) * 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
US20170342076A1 (en) * 2014-12-31 2017-11-30 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
CN108463463A (zh) * 2016-01-14 2018-08-28 韩德株式会社 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011082267A2 (en) * 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrazine compounds
GB201309333D0 (en) * 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010088518A2 (en) * 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN105142641A (zh) * 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
US20170342076A1 (en) * 2014-12-31 2017-11-30 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
CN108463463A (zh) * 2016-01-14 2018-08-28 韩德株式会社 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
周瑾 等: "咪唑并杂环化合物的设计、合成及抗乳腺癌活性评价" *

Also Published As

Publication number Publication date
US20220281873A1 (en) 2022-09-08
CN114072408B (zh) 2023-05-12
WO2021004467A1 (zh) 2021-01-14

Similar Documents

Publication Publication Date Title
TWI585088B (zh) 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JP2022543767A (ja) 四環式化合物、その調製と使用の方法
CA3069829A1 (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
TW202304911A (zh) 吡啶醯胺類化合物
CN110573500B (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
EP3753937B1 (en) Atr inhibitor and application thereof
TWI793999B (zh) 嘧啶並吡喃化合物
CN113490667B (zh) 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
JP7343622B2 (ja) Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としての縮合環系化合物
CN118055933A (zh) 选择性parp1抑制剂及其应用
JP2022532141A (ja) キナーゼ阻害剤として使用される化合物およびその応用
JP2021531290A (ja) アザインドール誘導体とＦＧＦＲ及びＣ−Ｍｅｔ阻害剤としてのその使用
CN114072408B (zh) 作为porcupine抑制剂的化合物及其应用
CN112601746A (zh) 吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用
JP7299350B2 (ja) Ｒｉｐ－１キナーゼ阻害剤としての二環式化合物およびその使用
CN115942937A (zh) 嘧啶并环类化合物
JP2021500370A (ja) 新規な大環状誘導体、それを調製するための方法及びそれを含有する医薬組成物
CN113316575B (zh) 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
CN110407854B (zh) 新的四环化合物
CN105722824A (zh) Rorγt的杂芳基连接的喹啉基调节剂
CN112839946A (zh) 作为TGF-βR1激酶抑制剂的双环吡唑类化合物
EP4206197A1 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
EP3766883B1 (en) Imidaxopyrolone compound and application thereof
CN117534663A (zh) 稠合的三并环衍生物及其在药学上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066300

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231024

Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangning City, Lianyungang, Jiangsu

Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.

TR01 Transfer of patent right